Vijay Pande leaves a16z to launch AI-focused VZVC, emphasizes open data for biotech

Vijay Pande, the former head of a16z’s $4 billion biotech practice, departed last year to launch the AI‑native venture VZVC. In a recent interview, Pande explained that the field of biology is moving from a discovery‑driven paradigm to one focused on engineering, where systematic design and rapid iteration become central. He cited the growing use of computational models and synthetic biology tools as evidence that biological research is increasingly becoming a precision engineering discipline.

Pande also highlighted the persistent cost barrier of clinical trials, noting that they remain “brutally expensive” despite advances in AI and automation. He argued that the high upfront investment and regulatory complexity continue to limit the speed at which new therapies reach patients. According to Pande, the key to accelerating medical breakthroughs lies in the availability of open, shared datasets. He warned that proprietary data silos inhibit the full potential of AI, whereas transparent, interoperable data repositories would enable broader collaboration and faster validation of AI‑driven insights.

In closing, Pande stressed that VZVC’s mission is to build an ecosystem that supports this data‑sharing model, positioning the firm as a catalyst for the next wave of engineering‑focused biology. He believes that by fostering open datasets and integrating AI from the earliest stages of research, the industry can reduce trial costs and bring innovative treatments to market more efficiently.